HUE042053T2 - Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére - Google Patents
Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezeléséreInfo
- Publication number
- HUE042053T2 HUE042053T2 HUE09757629A HUE09757629A HUE042053T2 HU E042053 T2 HUE042053 T2 HU E042053T2 HU E09757629 A HUE09757629 A HU E09757629A HU E09757629 A HUE09757629 A HU E09757629A HU E042053 T2 HUE042053 T2 HU E042053T2
- Authority
- HU
- Hungary
- Prior art keywords
- polypeptides
- virus
- treatment
- amino acid
- acid sequences
- Prior art date
Links
- 101710091045 Envelope protein Proteins 0.000 title 1
- 101710188315 Protein X Proteins 0.000 title 1
- 102100021696 Syncytin-1 Human genes 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1009—Picornaviridae, e.g. hepatitis A virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5905508P | 2008-06-05 | 2008-06-05 | |
US9299108P | 2008-08-29 | 2008-08-29 | |
US13913008P | 2008-12-19 | 2008-12-19 | |
US14465309P | 2009-01-14 | 2009-01-14 | |
US17291409P | 2009-04-27 | 2009-04-27 | |
US17410809P | 2009-04-30 | 2009-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE042053T2 true HUE042053T2 (hu) | 2019-06-28 |
Family
ID=41055279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE09757629A HUE042053T2 (hu) | 2008-06-05 | 2009-06-05 | Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére |
Country Status (17)
Country | Link |
---|---|
US (4) | US9193780B2 (hu) |
EP (2) | EP3424526A1 (hu) |
JP (2) | JP5809557B2 (hu) |
CN (1) | CN102112155B (hu) |
AU (1) | AU2009254501B2 (hu) |
CA (1) | CA2726652A1 (hu) |
CY (1) | CY1121687T1 (hu) |
DK (1) | DK2285408T3 (hu) |
ES (1) | ES2713864T3 (hu) |
HR (1) | HRP20182195T1 (hu) |
HU (1) | HUE042053T2 (hu) |
LT (1) | LT2285408T (hu) |
PL (1) | PL2285408T3 (hu) |
PT (1) | PT2285408T (hu) |
SI (1) | SI2285408T1 (hu) |
WO (1) | WO2009147248A2 (hu) |
ZA (1) | ZA201009135B (hu) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9193780B2 (en) | 2008-06-05 | 2015-11-24 | Ablynx N.V. | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases |
EP2364328A2 (en) | 2008-12-10 | 2011-09-14 | Ablynx NV | Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis |
ES2643034T3 (es) | 2009-06-05 | 2017-11-21 | Ablynx N.V. | Construcciones de Nanobody contra el virus respiratorio sincicial humano (VRSH) trivalentes para la prevención y/o el tratamiento de infecciones de las vías respiratorias |
AU2015200057B9 (en) * | 2009-06-05 | 2017-03-09 | Ablynx Nv | Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hRSV) Nanobody constructs for the prevention and/or treatment of respiratory tract infections |
US9644022B2 (en) | 2009-11-30 | 2017-05-09 | Ablynx N.V. | Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
AU2011214299B2 (en) | 2010-02-11 | 2014-07-31 | Ablynx Nv | Methods and compositions for the preparation of aerosols |
GB201014715D0 (en) * | 2010-09-06 | 2010-10-20 | Vib Vzw | Nanobodies stabilizing functional conformational states of GPCRS |
WO2012042026A1 (en) | 2010-09-30 | 2012-04-05 | Ablynx Nv | Biological materials related to c-met |
US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
US20120195900A1 (en) * | 2010-12-22 | 2012-08-02 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
JP2014525736A (ja) | 2011-06-23 | 2014-10-02 | アブリンクス エン.ヴェー. | IgEに対する免疫グロブリン単一可変ドメイン |
CN103619878B (zh) | 2011-06-23 | 2016-10-26 | 埃博灵克斯股份有限公司 | 结合血清白蛋白的蛋白 |
CN108659120A (zh) | 2011-06-23 | 2018-10-16 | 埃博灵克斯股份有限公司 | 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术 |
WO2013020074A2 (en) * | 2011-08-03 | 2013-02-07 | Children's Medical Center Corporation | A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin |
US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
UA115781C2 (uk) | 2012-02-27 | 2017-12-26 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cx3cr1-зв'язуючий поліпептид |
SI2831111T1 (sl) * | 2012-03-30 | 2019-06-28 | Boehringer Ingelheim International Gmbh | Ang2-vezavne molekule |
US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
US11339208B1 (en) | 2012-05-31 | 2022-05-24 | United States Of America As Represented By The Secretary Of The Air Force | Camelidae single-domain antibodies against Yersinia pestis and methods of use |
WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
EP2970397A2 (en) | 2013-03-14 | 2016-01-20 | University Of Washington Through Its Center For Commercialization | Polypeptides for treating and/or limiting influenza infection |
PT2970449T (pt) * | 2013-03-15 | 2019-11-06 | Amgen Res Munich Gmbh | Moléculas de ligação de cadeia única compreendendo abp n-terminal |
JP2016522168A (ja) * | 2013-04-05 | 2016-07-28 | ジェネンテック, インコーポレイテッド | 抗il−4抗体及び二重特異性抗体及びその使用 |
US9637542B2 (en) * | 2013-08-21 | 2017-05-02 | Boehringer Ingelheim International Gmbh | CX3CR1-targeting imaging agents and their use in the diagnosis and treatment of disease |
JP2016538852A (ja) * | 2013-11-25 | 2016-12-15 | オックスフォード バイオセラピューティックス リミテッドOxford Biotherapeutics Ltd | がん治療のための抗体抗マトリプターゼ |
EP3204041A1 (en) * | 2014-10-10 | 2017-08-16 | Ablynx N.V. | Methods of treating rsv infections |
CN114478753A (zh) | 2015-01-21 | 2022-05-13 | 英伊布里克斯公司 | 非免疫原性单结构域抗体 |
EA038407B1 (ru) * | 2015-02-05 | 2021-08-24 | Янссен Вэксинс Энд Превеншн Б.В. | Связывающие молекулы, направленные против гемагглютинина вируса гриппа, и пути их применения |
WO2016150845A1 (en) * | 2015-03-20 | 2016-09-29 | Ablynx Nv | Glycosylated immunoglobulin single variable domains |
MX2017012662A (es) | 2015-03-31 | 2018-05-11 | Vhsquared Ltd | Polipeptidos. |
WO2016156475A1 (en) * | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b |
AU2016263808B2 (en) | 2015-05-21 | 2019-01-03 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
EP3124042A1 (en) | 2015-07-28 | 2017-02-01 | VIB, vzw | Immunoglobulin single variable domain antibody against rsv prefusion f protein |
JP6836760B2 (ja) | 2015-06-18 | 2021-03-03 | フエー・イー・ベー・フエー・ゼツト・ウエー | Rsv融合前fタンパク質に対する免疫グロブリン単一可変ドメイン抗体 |
CN107922491B (zh) | 2015-07-16 | 2021-09-28 | 印希比股份有限公司 | 多价和多特异性结合dr5的融合蛋白 |
JP2017036258A (ja) * | 2015-08-07 | 2017-02-16 | パナソニックIpマネジメント株式会社 | インフルエンザウィルスに結合する抗体 |
JP6975709B2 (ja) * | 2015-09-02 | 2021-12-01 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 安定化したウイルスクラスi融合タンパク質 |
US10513553B2 (en) | 2015-11-13 | 2019-12-24 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
MX2018014227A (es) | 2016-05-20 | 2019-08-22 | Harpoon Therapeutics Inc | Proteinas de union de cadena unica de fragmento variable cd3. |
WO2017201488A1 (en) | 2016-05-20 | 2017-11-23 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
WO2018098354A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
EP3544629A4 (en) | 2016-11-23 | 2020-06-17 | Harpoon Therapeutics, Inc. | TRISPECIFIC PROTEINS CIBLANG PSMA AND METHODS OF USE |
WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
US10730954B2 (en) | 2017-05-12 | 2020-08-04 | Harpoon Therapeutics, Inc. | MSLN targeting trispecific proteins and methods of use |
BR112019023855B1 (pt) | 2017-05-12 | 2021-11-30 | Harpoon Therapeutics, Inc | Proteínas de ligação à mesotelina |
AU2017435322A1 (en) | 2017-10-11 | 2020-04-30 | Nanjing Legend Biotech Co., Ltd. | Compositions and methods for increasing protein half-life in a serum |
SG11202003341UA (en) | 2017-10-13 | 2020-05-28 | Harpoon Therapeutics Inc | B cell maturation antigen binding proteins |
EP3694529B1 (en) | 2017-10-13 | 2024-06-26 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
EP3784788A1 (en) * | 2018-04-23 | 2021-03-03 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Chimeric vectors |
CN108794626B (zh) * | 2018-06-18 | 2021-10-12 | 上海大学 | 一种多肽以及能靶向HIV包膜蛋白gp120的金纳米抗体 |
CN108640978A (zh) * | 2018-06-20 | 2018-10-12 | 上海大学 | 特异性结合HIV病毒上蛋白gp120的多肽及其应用 |
CN111333723B (zh) * | 2018-08-09 | 2022-03-15 | 北京智仁美博生物科技有限公司 | 针对狂犬病病毒g蛋白的单克隆抗体及其用途 |
JP7190675B2 (ja) | 2018-08-23 | 2022-12-16 | パナソニックIpマネジメント株式会社 | ノロウイルスに結合する抗体、複合体、それを用いた検出装置及び検出方法 |
JP7190674B2 (ja) | 2018-08-23 | 2022-12-16 | パナソニックIpマネジメント株式会社 | ノロウイルスに結合する抗体、複合体、それを用いた検出装置及び検出方法 |
CN109097341B (zh) * | 2018-08-28 | 2021-09-24 | 青岛农业大学 | 一种同时表达ha和hef的复制缺陷型重组流感病毒 |
JP7425049B2 (ja) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | Dll3結合タンパク質および使用方法 |
CA3116292A1 (en) * | 2018-10-25 | 2020-04-30 | Km Biologics Co., Ltd. | Modified cmv gb protein and cmv vaccine including same |
CA3132521A1 (en) | 2019-03-25 | 2020-10-01 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
US20220242945A1 (en) | 2019-06-21 | 2022-08-04 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
AU2020294980A1 (en) | 2019-06-21 | 2022-02-17 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
CN111393512B (zh) * | 2020-03-24 | 2021-03-02 | 北京中科微盾生物科技有限责任公司 | 一种抑制流感病毒的多肽及其在制备预防和治疗流感病毒感染药物中的应用 |
CN116171384A (zh) * | 2020-08-19 | 2023-05-26 | 匹兹堡大学 联邦高等教育系统 | 冠状病毒纳米抗体及其使用和鉴定方法 |
US20240109963A1 (en) * | 2020-11-16 | 2024-04-04 | Ab Therapeutics, Inc. | Multispecific antibodies and uses thereof |
CN112851811B (zh) * | 2021-01-28 | 2022-08-09 | 姜国胜 | 一种cd44v6纳米抗体及其作为白血病研究试剂的应用 |
CN113234151B (zh) * | 2021-06-08 | 2022-02-15 | 皖南医学院第一附属医院(皖南医学院弋矶山医院) | 一种基于靶向SARS-CoV2病毒S蛋白的三聚体纳米抗体的CAR-NK的研制 |
US11970548B2 (en) * | 2021-08-27 | 2024-04-30 | Innovative Cellular Therapeutics Holdings, Ltd. | Nanobody target GCC and uses in chimeric antigen receptor cell therapy |
WO2023039528A1 (en) * | 2021-09-10 | 2023-03-16 | The Board Of Trustees Of The Leland Stanford Junior University | Nanobody-mediated control of gene expression and epigenetic memory |
WO2023177821A2 (en) * | 2022-03-16 | 2023-09-21 | Myeloid Therapeutics, Inc. | Binding domains and methods of use thereof |
WO2024068744A1 (en) * | 2022-09-27 | 2024-04-04 | Vib Vzw | Antivirals against human parainfluenza virus |
WO2024133935A1 (en) | 2022-12-23 | 2024-06-27 | Ablynx Nv | Protein-based conjugation carriers |
CN116375852B (zh) * | 2023-03-10 | 2024-02-02 | 华南农业大学 | 重组荧光纳米抗体及其在制备狂犬病病毒检测试剂中的应用 |
CN116751284B (zh) * | 2023-06-13 | 2024-06-04 | 康元医疗科技(大连)有限公司 | 一种纳米抗体、包含该纳米抗体的多肽及其应用 |
CN116987194B (zh) * | 2023-09-26 | 2023-12-26 | 江西乐成欣生生物技术研究有限责任公司 | 人st2抗原的模拟表位肽的抗独特型纳米抗体及应用 |
CN117843801A (zh) * | 2023-12-29 | 2024-04-09 | 北京贝来药业有限公司 | 以白介素家族成员为靶点的新型抗体以及下游产品 |
CN117986360A (zh) * | 2024-02-01 | 2024-05-07 | 生物岛实验室 | Il18蛋白的特异性抗体及其制备方法与应用 |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1120945A (en) | 1964-08-11 | 1968-07-24 | Fisons Pharmaceuticals Ltd | Applicator in combination with a pressurised aerosol dispensing container |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
US5824307A (en) * | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
CA2135408A1 (en) | 1992-05-08 | 1993-11-25 | Peter C. Keck | Chimeric multivalent protein analogues and methods of use thereof |
US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
US6020182A (en) | 1996-07-12 | 2000-02-01 | Connaught Laboratories Limited | Subunit respiratory syncytial virus vaccine preparation |
CA2270288A1 (en) | 1996-11-01 | 1998-05-14 | Smithkline Beecham Corporation | Human monoclonal antibodies |
US7122636B1 (en) * | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
AU3596599A (en) | 1998-01-26 | 1999-08-09 | Unilever Plc | Method for producing antibody fragments |
EP1144616B2 (en) | 1999-01-19 | 2009-01-14 | Unilever Plc | Method for producing antibody fragments |
AP1447A (en) | 1999-04-22 | 2005-08-12 | Unilever Plc | Inhibition of viral infection using monovalent antigen-binding proteins. |
US6133571A (en) * | 1999-04-26 | 2000-10-17 | Lockheed Martin Corporation | Resonant cavity field enhancing boundary |
US7550143B2 (en) * | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
AR030019A1 (es) | 1999-05-18 | 2003-08-13 | Smithkline Beecham Corp | Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m |
CA2390691C (en) | 1999-12-24 | 2016-05-10 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US20030190598A1 (en) | 2000-05-26 | 2003-10-09 | Jasmid Tanha | Single-domain antigen-binding antibody fragments derived from llama antibodies |
WO2002057445A1 (en) | 2000-05-26 | 2002-07-25 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
US6818216B2 (en) * | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
JP4336771B2 (ja) | 2001-03-09 | 2009-09-30 | モルフォシス アーゲー | 血清アルブミン結合部分 |
GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
WO2003025020A1 (fr) | 2001-09-13 | 2003-03-27 | Institute For Antibodies Co., Ltd. | Procede pour creer une banque d'anticorps de chameaux |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
WO2003050531A2 (en) | 2001-12-11 | 2003-06-19 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
CA2468690A1 (en) * | 2001-12-18 | 2003-06-26 | Innogenetics N.V. | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
AU2002360068B2 (en) | 2001-12-21 | 2009-09-03 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Method for cloning of variable domain sequences |
AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
EP1600459A3 (en) | 2002-06-28 | 2005-12-07 | Domantis Limited | Ligand |
GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
AU2003285578B2 (en) | 2002-12-03 | 2010-07-15 | Ucb Pharma S.A. | Assay for identifying antibody producing cells |
EP1639009B1 (en) * | 2003-05-30 | 2013-02-27 | Merus B.V. | Fab library for the preparation of a mixture of antibodies |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
US7070786B2 (en) | 2003-06-06 | 2006-07-04 | Centocor, Inc. | RSV proteins, antibodies, compositions, methods and uses |
AU2003264053A1 (en) | 2003-08-12 | 2005-03-10 | William M. Yarbrough | Treatment for acne vulgaris and method of use |
ATE554390T1 (de) | 2003-08-20 | 2012-05-15 | Ucb Pharma Sa | Verfahren zur gewinnung von antikörpern |
CA2554054C (en) * | 2004-01-20 | 2013-06-04 | Merus B.V. | Mixtures of binding proteins |
AU2005214988A1 (en) * | 2004-02-17 | 2005-09-01 | Absalus, Inc. | Super-humanized antibodies against respiratory syncytial virus |
BRPI0512235A (pt) | 2004-06-18 | 2008-02-19 | Ambrx Inc | polipeptìdeos ligadores de antìgenos e seus usos |
US20050279676A1 (en) | 2004-06-21 | 2005-12-22 | Izzy Zuhair A | Fluid filter assembly for a dispensing faucet |
EP3272770B1 (en) | 2004-07-22 | 2023-12-20 | Erasmus University Medical Center Rotterdam | Method for the production of a vh heavy chain-only antibody in a transgenic mammal and binding polypeptide complex consisting of a dimer of a first chain and a second chain wherein each chain consists of two antigen-specific vh binding domains linked by a dimerisation domain |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
AU2005286770A1 (en) * | 2004-09-21 | 2006-03-30 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
RU2007117752A (ru) | 2004-10-13 | 2008-11-20 | Аблинкс Н.В. (Be) | Нанотела (nanobodies тм) против бета-амилоида и полипептидов, содержащих бета-амилоид, для лечения нейродегенеративных заболеваний, таких как болезнь альцгеймера |
WO2006040154A2 (en) | 2004-10-14 | 2006-04-20 | Dublin City University | Prokaryotic two hybrid system |
TW200636064A (en) | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
CA2585891A1 (en) | 2004-10-29 | 2006-05-11 | Medimmune, Inc. | Methods of preventing and treating rsv infections and related conditions |
JP2008528010A (ja) | 2005-01-31 | 2008-07-31 | アブリンクス ナームローゼ フェンノートシャップ | 重鎖抗体の可変ドメイン配列を作出する方法 |
CA2604032C (en) | 2005-04-06 | 2017-08-22 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
JP4976376B2 (ja) * | 2005-04-08 | 2012-07-18 | メディミューン,エルエルシー | 哺乳動物メタニューモウイルスに対する抗体 |
US20090286727A1 (en) | 2006-04-14 | 2009-11-19 | Ablynx N.V. | DP-78-Like Nanobodies |
EP2040995A1 (en) | 2006-06-26 | 2009-04-01 | Aida Centre, S.L. | Blister package integrating rfid based tags |
AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
JP2010507624A (ja) | 2006-10-27 | 2010-03-11 | アブリンクス エン.ヴェー. | ポリペプチド及びタンパク質の鼻内送達 |
CN101611056A (zh) | 2006-12-05 | 2009-12-23 | 埃博灵克斯股份有限公司 | 能够结合于血清蛋白的肽 |
CA2672944A1 (en) | 2006-12-22 | 2008-07-03 | Ablynx N.V. | Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders |
EP2096121A1 (en) * | 2008-02-29 | 2009-09-02 | Institut Pasteur Of Shanghai | Antiviral peptides comprising lipid attachment signals and methods of use |
US9193780B2 (en) | 2008-06-05 | 2015-11-24 | Ablynx N.V. | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases |
PT2387583T (pt) | 2009-01-14 | 2018-12-24 | Ablynx Nv | Administração pulmonar de domínios de variável única de imunoglobulina e construtos dos mesmos |
AU2010243551B2 (en) | 2009-04-30 | 2015-03-26 | Ablynx Nv | Method for the production of domain antibodies |
ES2643034T3 (es) | 2009-06-05 | 2017-11-21 | Ablynx N.V. | Construcciones de Nanobody contra el virus respiratorio sincicial humano (VRSH) trivalentes para la prevención y/o el tratamiento de infecciones de las vías respiratorias |
US9644022B2 (en) | 2009-11-30 | 2017-05-09 | Ablynx N.V. | Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
-
2009
- 2009-06-05 US US12/996,074 patent/US9193780B2/en active Active
- 2009-06-05 JP JP2011512149A patent/JP5809557B2/ja not_active Expired - Fee Related
- 2009-06-05 AU AU2009254501A patent/AU2009254501B2/en not_active Ceased
- 2009-06-05 CA CA2726652A patent/CA2726652A1/en not_active Abandoned
- 2009-06-05 HU HUE09757629A patent/HUE042053T2/hu unknown
- 2009-06-05 SI SI200931914T patent/SI2285408T1/sl unknown
- 2009-06-05 LT LTEP09757629.2T patent/LT2285408T/lt unknown
- 2009-06-05 ES ES09757629T patent/ES2713864T3/es active Active
- 2009-06-05 DK DK09757629.2T patent/DK2285408T3/en active
- 2009-06-05 EP EP18189511.1A patent/EP3424526A1/en not_active Withdrawn
- 2009-06-05 EP EP09757629.2A patent/EP2285408B1/en active Active
- 2009-06-05 WO PCT/EP2009/056975 patent/WO2009147248A2/en active Application Filing
- 2009-06-05 PT PT09757629T patent/PT2285408T/pt unknown
- 2009-06-05 PL PL09757629T patent/PL2285408T3/pl unknown
- 2009-06-05 CN CN200980130125.3A patent/CN102112155B/zh not_active Expired - Fee Related
-
2010
- 2010-12-20 ZA ZA2010/09135A patent/ZA201009135B/en unknown
-
2015
- 2015-04-30 JP JP2015093215A patent/JP2015156867A/ja active Pending
- 2015-10-29 US US14/926,381 patent/US9834595B2/en active Active
-
2017
- 2017-10-17 US US15/785,604 patent/US10550174B2/en active Active
-
2018
- 2018-12-28 HR HRP20182195TT patent/HRP20182195T1/hr unknown
-
2019
- 2019-01-15 CY CY20191100039T patent/CY1121687T1/el unknown
- 2019-08-01 US US16/528,837 patent/US11518799B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2009147248A3 (en) | 2010-07-15 |
US11518799B2 (en) | 2022-12-06 |
EP2285408B1 (en) | 2018-10-24 |
US9834595B2 (en) | 2017-12-05 |
US20200123233A1 (en) | 2020-04-23 |
US20190077847A1 (en) | 2019-03-14 |
CN102112155A (zh) | 2011-06-29 |
US20160152693A1 (en) | 2016-06-02 |
EP2285408A2 (en) | 2011-02-23 |
US20110182897A1 (en) | 2011-07-28 |
ZA201009135B (en) | 2012-06-27 |
HRP20182195T1 (hr) | 2019-02-22 |
US9193780B2 (en) | 2015-11-24 |
WO2009147248A2 (en) | 2009-12-10 |
AU2009254501B2 (en) | 2014-07-31 |
SI2285408T1 (sl) | 2019-02-28 |
CA2726652A1 (en) | 2009-12-10 |
AU2009254501A1 (en) | 2009-12-10 |
LT2285408T (lt) | 2019-01-25 |
US10550174B2 (en) | 2020-02-04 |
CN102112155B (zh) | 2016-08-10 |
JP2011521662A (ja) | 2011-07-28 |
JP2015156867A (ja) | 2015-09-03 |
EP3424526A1 (en) | 2019-01-09 |
ES2713864T3 (es) | 2019-05-24 |
PL2285408T3 (pl) | 2019-05-31 |
JP5809557B2 (ja) | 2015-11-11 |
PT2285408T (pt) | 2019-02-01 |
DK2285408T3 (en) | 2019-02-04 |
CY1121687T1 (el) | 2020-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20182195T1 (hr) | Sekvence aminokiselina usmjerene protiv virusnih proteina ovojnice i polipeptidi koji sadrže iste za liječenje virusnih bolesti | |
IL251916A0 (en) | Improved amino acid sequences directed against il-6r and polypeptides containing them for the treatment of il-6r-related diseases and disorders | |
IL201842A0 (en) | Novel peptide inhibitors of hepatitis c virus replication | |
HK1201276A1 (en) | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders rank-l | |
IL222997A0 (en) | Soluble fragments of influenza virus pb2 protein capable of binding rna - cap | |
PL2010572T3 (pl) | Białka fuzyjne zawierające polipeptydy HPV i peptydy wzmagające odporność do leczenia i zapobiegania rakowi szyjki macicy | |
ZA200808845B (en) | Novel DNA sequences, vectors and proteins of Avian Influenza hemagglutinin | |
HK1150168A1 (en) | Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors | |
EP2091960A4 (en) | PEPTIDE VACCINE AGAINST INFLUENZA VIRUS | |
IL205238A0 (en) | Directed evolution using proteins comprising unnatural amino acids | |
IL226771A0 (en) | Recombinant elastase protein, the methods for its production and its use | |
EP1893233A4 (en) | PEPTIDES AND THERAPEUTIC VACCINES | |
EP1841451A4 (en) | PEPTIDES FOR THE DELIVERY OF MUCOUS VACCINES | |
EP1871786A4 (en) | PEPTIDE VACCINE AGAINST THE GRIPPEVIRUS | |
IL215316A (en) | Medications containing tat hiv-derived amino acid sequences and their use in cancer treatment | |
WO2006018431A3 (en) | Peptides for the treatment of herpes virus infections | |
EP2097090A4 (en) | PEPTIDE AND TREATMENT FOR HIV-1 INFECTION | |
ZA201200046B (en) | Therapeutic peptides, polypeptides and nucleic acid sequences | |
ZA200800566B (en) | Therapeutic peptides and vaccines | |
EP2244725A4 (en) | NOVEL PEPTIDES AND PROTEIN AND USE THEREOF | |
IL201676A0 (en) | Oral delivery of proteins and peptides | |
EG27024A (en) | Natural or recombinant proteins for treatment and diagnosis of hepatitis C virus | |
GB0912155D0 (en) | Therapeutic peptides, polypeptides and nucleic acid sequences | |
GB0921328D0 (en) | Therapeutic peptides, polypeptides and nucleic acid sequences | |
HK1106144A1 (en) | Peptides for the treatment of herpes virus infections |